These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9987141)

  • 61. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.
    Villa M; Black S; Groth N; Rothman KJ; Apolone G; Weiss NS; Aquino I; Boldori L; Caramaschi F; Gattinoni A; Malchiodi G; Crucitti A; Della Cioppa G; Scarpini E; Mavilio D; Mannino S
    Am J Epidemiol; 2013 Oct; 178(7):1139-45. PubMed ID: 23863759
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
    Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults.
    Boyce TG; Hsu HH; Sannella EC; Coleman-Dockery SD; Baylis E; Zhu Y; Barchfeld G; DiFrancesco A; Paranandi M; Culley B; Neuzil KM; Wright PF
    Vaccine; 2000 Sep; 19(2-3):217-26. PubMed ID: 10930676
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects.
    Gasparini R; Pozzi T; Montomoli E; Fragapane E; Senatore F; Minutello M; Podda A
    Eur J Epidemiol; 2001; 17(2):135-40. PubMed ID: 11599686
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults.
    Durando P; Fenoglio D; Boschini A; Ansaldi F; Icardi G; Sticchi L; Renzoni A; Fabbri P; Ferrera A; Parodi A; Bruzzone B; Gabutti G; Podda A; Del Giudice G; Fragapane E; Indiveri F; Crovari P; Gasparini R
    Clin Vaccine Immunol; 2008 Feb; 15(2):253-9. PubMed ID: 18003811
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy.
    Iorio AM; Francisci D; Camilloni B; Stagni G; De Martino M; Toneatto D; Bugarini R; Neri M; Podda A
    Vaccine; 2003 Sep; 21(25-26):3629-37. PubMed ID: 12922092
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly.
    Pregliasco F; Mensi C; Serpilli W; Speccher L; Masella P; Belloni A
    Aging (Milano); 2001 Feb; 13(1):38-43. PubMed ID: 11292151
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vaccine-Preventable Diseases in Older Adults.
    Al-Jabri M; Rosero C; Saade EA
    Infect Dis Clin North Am; 2023 Mar; 37(1):103-121. PubMed ID: 36805008
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of three different influenza vaccines in institutionalised elderly.
    Baldo V; Menegon T; Bonello C; Floreani A; Trivello R;
    Vaccine; 2001 May; 19(25-26):3472-5. PubMed ID: 11348713
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant.
    Keitel W; Couch R; Bond N; Adair S; Van Nest G; Dekker C
    Vaccine; 1993; 11(9):909-13. PubMed ID: 8212835
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season.
    Amicizia D; Domnich A; Lai PL; Orsi A; Icardi G; Tkach-Motulyak O; Panatto D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2190279. PubMed ID: 36919537
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects.
    Li R; Fang H; Li Y; Liu Y; Pellegrini M; Podda A
    Immun Ageing; 2008 Feb; 5():2. PubMed ID: 18289372
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant.
    Heineman TC; Clements-Mann ML; Poland GA; Jacobson RM; Izu AE; Sakamoto D; Eiden J; Van Nest GA; Hsu HH
    Vaccine; 1999 Jul; 17(22):2769-78. PubMed ID: 10438046
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inactivated and adjuvanted influenza vaccines.
    Del Giudice G; Rappuoli R
    Curr Top Microbiol Immunol; 2015; 386():151-80. PubMed ID: 25038938
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children.
    Stassijns J; Bollaerts K; Baay M; Verstraeten T
    Vaccine; 2016 Feb; 34(6):714-22. PubMed ID: 26740250
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.
    Kompier R; Neels P; Beyer W; Hardman T; Lioznov D; Kharit S; Kostinov M
    F1000Res; 2022; 11():259. PubMed ID: 36176546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.